- Home
- EXEL vs NVVEW Comparison
EXEL vs NVVEW Comparison
Compare EXEL & NVVEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- NVVEW
- Stock Information
- Founded
- EXEL 1994
- NVVEW N/A
- Country
- EXEL United States
- NVVEW China
- Employees
- EXEL N/A
- NVVEW 12
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- NVVEW Oil Refining/Marketing
- Sector
- EXEL Health Care
- NVVEW Energy
- Exchange
- EXEL Nasdaq
- NVVEW Nasdaq
- Market Cap
- EXEL 9.8B
- NVVEW N/A
- IPO Year
- EXEL 2000
- NVVEW 2020
- Fundamental
- Price
- EXEL $36.17
- NVVEW $0.05
- Analyst Decision
- EXEL Buy
- NVVEW
- Analyst Count
- EXEL 18
- NVVEW 0
- Target Price
- EXEL $37.59
- NVVEW N/A
- AVG Volume (30 Days)
- EXEL 2.2M
- NVVEW N/A
- Earning Date
- EXEL 05-13-2025
- NVVEW N/A
- Dividend Yield
- EXEL N/A
- NVVEW N/A
- EPS Growth
- EXEL 170.77
- NVVEW N/A
- EPS
- EXEL 1.76
- NVVEW N/A
- Revenue
- EXEL $2,168,701,000.00
- NVVEW N/A
- Revenue This Year
- EXEL $5.78
- NVVEW N/A
- Revenue Next Year
- EXEL $10.94
- NVVEW N/A
- P/E Ratio
- EXEL $20.64
- NVVEW N/A
- Revenue Growth
- EXEL 18.50
- NVVEW N/A
- 52 Week Low
- EXEL $20.14
- NVVEW N/A
- 52 Week High
- EXEL $40.26
- NVVEW N/A
- Technical
- Relative Strength Index (RSI)
- EXEL 43.89
- NVVEW N/A
- Support Level
- EXEL $34.90
- NVVEW N/A
- Resistance Level
- EXEL $40.26
- NVVEW N/A
- Average True Range (ATR)
- EXEL 1.21
- NVVEW 0.00
- MACD
- EXEL -0.19
- NVVEW 0.00
- Stochastic Oscillator
- EXEL 23.69
- NVVEW 0.00
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About NVVEW Nuvve Holding Corp. Warrant
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.